Novogene Agrees to Buy Ten PacBio Sequel Systems for DNA Sequencing Services
January 16 2017 - 3:00PM
Pacific Biosciences of California, Inc. (Nasdaq:PACB) and Novogene
Corporation, a leading provider of genomic and bioinformatic
services, today announced that Novogene has agreed to purchase 10
Sequel™ Systems for whole genome sequencing, Iso-Seq™ annotation
and targeted sequencing services.
PacBio’s sequencing systems are based on its unique Single
Molecule, Real-Time (SMRT®) technology, and provide an unmatched
depth of genetic information through exceptionally long sequencing
reads, uniform coverage, and the highest consensus accuracy
available today. The technology allows scientists to go beyond
fragmented draft genomes and generate the most
comprehensive de novo assemblies.
Ruiqiang Li, Ph.D., Founder and CEO of
Novogene commented: “Novogene is a global leader in de novo
sequencing and assembly today, and our purchase of ten PacBio
Sequel Systems will advance our ability to produce even higher
quality and more complete de novo genome assemblies. The addition
of these systems, and the ability to sequence large genomic
libraries that yield mean read lengths of 10-18kb, also will enable
us to meet the growing demand for SMRT Sequencing and to deliver
more cost-effective de novo sequencing and assembly solutions for
our customers. With this purchase, we expect to have the world’s
largest SMRT Sequencing facility.”
Michael J. Hunkapiller, Ph.D., Chairman and CEO of PacBio added:
“We are delighted to receive such a significant endorsement of our
technology from a world-class sequencing facility. This follows a
recent trend by leading institutions around the world investing in
multiple SMRT Sequencing systems— oftentimes to complement their
existing PacBio RS II instruments. Moreover, it underscores that
adoption of SMRT Sequencing to answer some of the most challenging
questions in genomics and medicine is increasing
steadily.”
Novogene will announce its purchase of the PacBio Sequel systems
today at its workshop at the Plant and Animal Genome XXV Conference
in San Diego, where Novogene will be discussing how SMRT technology
and other cutting edge sequencing technologies help improve the
results of de novo assemblies for a variety of species. Novogene’s
workshop – Latest NGS Applications in Agricultural Research – is
being conducted Monday, January 16, 2017 from 6:10 PM to 8:20 PM in
the Pacific Salon 1 at the Town and Country Hotel.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB)
offers sequencing systems to help scientists resolve genetically
complex problems. Based on its novel Single Molecule, Real-Time
(SMRT®) technology, Pacific Biosciences’ products enable: de novo
genome assembly to finish genomes in order to more fully identify,
annotate and decipher genomic structures; full-length transcript
analysis to improve annotations in reference genomes, characterize
alternatively spliced isoforms in important gene families, and find
novel genes; targeted sequencing to more comprehensively
characterize genetic variations; and real-time kinetic information
for epigenome characterization. Pacific Biosciences’ technology
provides high accuracy, ultra-long reads, uniform coverage, and is
the only DNA sequencing technology that provides the ability to
simultaneously detect epigenetic changes. PacBio® sequencing
systems, including consumables and software, provide a simple,
fast, end-to-end workflow for SMRT Sequencing. More information is
available at www.pacb.com.
About Novogene Corporation
Novogene is a leading provider of genomic services and solutions
with cutting edge NGS and bioinformatics expertise and one of the
largest sequencing capacities in the world. Novogene utilizes
scientific excellence, a commitment to customer service and
unsurpassed data quality to help our clients realize their research
goals in the rapidly evolving world of genomics. With 1,300
employees, multiple locations around the world, 43 NGS related
patents, and over 200 publications in top tier journal such as
Nature and Science, the company has rapidly become a world-leader
in NGS services. For more information,
visit https://en.novogene.com/
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to product orders, future uses, quality or
performance of, or benefits of using, products or technologies, the
expected benefits of the company’s agreement with Novogene, the
suitability of the company’s products for particular markets or
applications and other future events. You should not place undue
reliance on forward-looking statements because they involve known
and unknown risks, uncertainties, changes in circumstances and
other factors that are, in some cases, beyond Pacific Biosciences’
control and could cause actual results to differ materially from
the information expressed or implied by forward-looking statements
made in this press release. Factors that could materially affect
actual results can be found in Pacific Biosciences’ most recent
filings with the Securities and Exchange Commission, including
Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and
10-Q, and include those listed under the caption “Risk
Factors.”
Pacific Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
Contacts for PacBio:
Media:
Nicole Litchfield
415.793.6468
nicole@bioscribe.com
Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com
For Novogene:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2024 to May 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From May 2023 to May 2024